| Paediatric | Adult | Total |
---|---|---|---|
 | (N = 107) | (N = 262) | (N = 369) |
Sex | |||
 Male | 54 (50%) | 107 (41%) | 161 (44%) |
 Female | 53 (50%) | 155 (59%) | 208 (56%) |
Median Age, years (range) | 10 (0.5–17) | 40 (18–88) | 30 (0.5–88) |
Number of ED visits for anaphylaxis during study period | |||
 1 | 98 (95%) | 232 (94%) | 330 (94%) |
 2 | 3 (4%) | 9 (5%) | 12 (5%) |
 3 | 1 (1%) | 4 (2%) | 5 (1%) |
Arrival mode to ED | |||
 Self | 52 (49%) | 145 (55%) | 197 (53%) |
 Ambulance | 55 (51%) | 117 (45%) | 172 (47%) |
Initial ED presentation site | |||
 Tertiary ED | 88 (82%) | 188 (72%) | 276 (75%) |
 Community ED | 19 (18%) | 74 (28%) | 93 (25%) |
Received adrenaline prior to ED presentation | 46 (43%) | 94 (36%) | 140 (38%) |
Met ASCIA anaphylaxis criteria prior to arrival to ED | 94 (88%) | 240 (92%) | 334 (91%) |
Met ASCIA anaphylaxis criteria on arrival to ED | 52 (49%) | 159 (61%) | 211 (57%) |
Anaphylaxis severity | |||
 Mild | 6 (6%) | 10 (4%) | 16 (4%) |
 Moderate | 91 (85%) | 193 (74%) | 284 (77%) |
 Severe | 10 (9%) | 59 (22%) | 69 (19%) |
Suspected Trigger | |||
 Food | 74 (69%) | 95 (36%) | 169 (46%) |
 Venom | 7 (7%) | 42 (16%) | 49 (13%) |
 Medication | 5 (5%) | 43 (16%) | 48 (13%) |
 Other | 5 (5%) | 16 (6%) | 21 (6%) |
 Unknown | 16 (15%) | 66 (25%) | 82 (22%) |
Reacted to previously identified trigger | 51 (53%) | 82 (40%) | 133 (44%) |
Previous anaphylaxis | 65 (61%) | 128 (49%) | 193 (52%) |
Previously seen immunologist | 47 (44%) | 75 (29%) | 122 (33%) |
Comorbid conditions | |||
 Asthma | 34 (32%) | 73 (28%) | 107 (29%) |
 Eczema | 19 (18%) | 12 (5%) | 31 (8%) |
 Allergic rhinitis | 3 (3%) | 14 (5%) | 17 (5%) |
 Cardiovascular disease | 1 (1%) | 57 (22%) | 58 (16%) |
 Cognitive impairment | 1 (1%) | 4 (2%) | 5 (1%) |
 Substance abuse | 0 (0%) | 11 (4%) | 11 (3%) |